

LINCOLN PHARMACEUTICALS LIMITED

"LINCOLN HOUSE", B/H. SATYAM COMPLEX, SCIENCE CITY ROAD, SOLA, AHMEDABAD-380060

UN-AUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED ON 30.09.2011

(₹ in Lacs.)

PARTICULARS	CONSOLIDATED					STANDALONE				
	QUARTER ENDED		SIX MONTH ENDED		Year ended	QUARTER ENDED		SIX MONTH ENDED		Year ended
	30.09.2011 (Un-Audited)	30.09.2010 (Un-Audited)	30.09.2011 (Un-Audited)	30.09.2010 (Un-Audited)	31.03.2011 (Audited)	30.09.2011 (Un-Audited)	30.09.2010 (Un-Audited)	30.09.2011 (Un-Audited)	30.09.2010 (Un-Audited)	31.03.2011 (Audited)
Sales	4625.64	4472.75	8680.18	7731.83	18378.57	4613.47	4457.47	8313.60	7704.34	17270.03
Other Income	96.48	63.92	165.95	98.22	203.20	96.48	63.92	155.98	98.22	203.20
Total Expenditure										
(a) (Increase)/decrease in stock	-255.29	-391.37	-290.76	-688.39	(135.28)	-255.29	-391.37	-186.12	-688.39	(30.64)
(b) Consumption of Raw Materials	2671.73	2383.29	5174.00	4014.36	12164.72	2657.97	2379.31	4948.33	4004.49	11000.22
(c) Staff Cost	386.76	367.84	758.89	672.13	1445.28	386.76	367.84	758.89	672.13	1444.68
(d) Other Expenditure	710.72	860.08	1595.04	1600.02	3798.83	706.01	857.06	1570.38	1593.75	3772.07
Gross Profit before Tax, Interest and Depreciation	697.62	534.09	1027.44	855.15	1308.22	703.92	525.81	1005.86	843.80	1286.90
Interest	233.80	97.21	327.00	179.93	317.99	233.67	97.21	325.75	179.26	317.17
Profit before Depreciation & Tax	463.82	436.88	700.44	675.22	990.23	470.25	428.60	680.11	664.54	969.73
Depreciation	40.08	39.36	82.46	69.36	166.68	40.08	39.36	82.46	69.36	166.68
Profit before Tax	423.74	397.52	617.98	605.86	823.55	430.17	389.24	597.65	595.18	803.05
Provision for Taxation	212.30	114.12	193.90	173.93	238.57	214.48	114.12	186.98	173.93	231.57
Net Profit after Tax	211.44	283.40	424.08	431.93	584.98	215.69	275.12	410.67	421.25	571.48
Extra Ordinary Item (Prior period expenses)	40.65	-----	40.65	-----	168.34	40.65	-----	40.65	-----	168.34
Net Profit after Extra ordinary Items	170.79	283.40	383.43	431.93	416.64	175.04	275.12	370.02	421.25	403.14
Equity shares Capital	1631.08	1131.08	1631.08	1131.08	1631.08	1631.08	1131.08	1631.08	1131.08	1631.08
Reserves and Surplus (Excluding Revaluation Reserve)	-----	-----	-----	-----	6050.51	-----	-----	-----	-----	6003.72
Earning Per Share (EPS) (F.V. Rs.10):-										
a) Basic and diluted EPS before Extraordinary items.(Not Annualised)	1.30	2.50	2.60	3.82	4.22	1.32	2.43	2.52	3.72	4.14
b) Basic and diluted EPS after Extraordinary items.(Not Annualised)	1.05	2.50	2.35	3.82	3.00	1.07	2.43	2.27	3.72	2.92
Public Shareholding:										
-Number of shares	12308100	7808100	12308100	7808100	12308100	12308100	7808100	12308100	7808100	12308100
-Percentage of Shareholding	75.46	69.03	75.46	69.03	75.46	75.46	69.03	75.46	69.03	75.46
Promoters and Promoter group Shareholding:										
a) Pledged/Encumbered										
-Number of shares	NIL	699400	NIL	699400	699400	NIL	699400	NIL	699400	699400
-Percentage of Shareholding (as a %of the total shareholding of promoter and promoter group)	NIL	19.97	NIL	19.97	17.47	NIL	19.97	NIL	19.97	17.47
-Percentage of Shareholding (as a %of the total share capital of the Company)	NIL	6.18	NIL	6.18	4.29	NIL	6.18	NIL	6.18	4.29
b) Non-encumbered										
-Number of shares	4002700	2803300	4002700	2803300	3303300	4002700	2803300	4002700	2803300	3303300
-Percentage of Shareholding (as a %of the total shareholding of promoter and promoter group)	100.00	80.03	100.00	80.03	82.53	100.00	80.03	100.00	80.03	82.53
-Percentage of Shareholding (as a %of the total share capital of the Company)	24.54	24.79	24.54	24.79	20.25	24.54	24.79	24.54	24.79	20.25

NOTES:

- The above results have been taken on record by the Board of Directors at its meeting held on 12.11.2011
- Since the revenue from different segment is less than 10% of total revenue, segment wise results are not given.
- The Company has received and disposed off three investors complaints/queries during the quarter.
- The Company has one WOS namely Zullinc Healthcare Limited as at 30.09.2011.

5. Statement of Assets and Liabilities is as under:

(₹ in Lacs.)

Particulars	Consolidated			Standalone		
	As at 30.09.11 (Un-Audited)	As at 30.09.10 (Un-Audited)	As at 31.03.11 (Audited)	As at 30.09.11 (Un-Audited)	As at 30.09.10 (Un-Audited)	As at 31.03.11 (Audited)
1. Shareholders' Fund						
a) Share Capital	1631.08	1131.08	1631.08	1631.08	1131.08	1631.08
b) Reserves and Surplus	6430.43	4629.47	6050.51	6373.72	4585.57	6003.72
2. Loan Funds	4375.86	3646.87	4209.70	4370.86	3646.87	4209.70
3. Deferred tax liability	486.71	289.85	430.55	486.71	289.85	430.55
Total	12924.08	9697.27	12321.84	12862.37	9653.37	12275.05
1. Fixed Assets	3462.77	2656.72	3227.87	3462.77	2656.72	3227.87
2. Investments	0.34	0.34	0.34	0.19	5.19	5.19
3. Current Assets, Loans and Advances						
a) Inventories	2407.38	1674.15	2606.77	2407.38	1674.15	2502.13
b) Sundry Debtors	5152.56	4817.82	3933.37	5131.42	4783.57	3912.65
c) Cash and Bank Balances	449.52	884.02	1128.27	429.28	874.91	1119.92
d) Loan and Advances	5794.03	3202.74	5178.39	5656.33	3152.05	5150.64
Misc. Expenditure (Not written off or Adjusted)	---	1.02	0.61	---	---	---
Less: Current Liabilities and Provisions	(4342.52)	(3539.54)	(3753.78)	(4225.00)	(3493.22)	(3643.35)
Total	12924.08	9697.27	12321.84	12862.37	9653.37	12275.05

Place : Ahmedabad.

Date : 12.11.2011

For LINCOLN PHARMACEUTICALS LIMITED

sd/
(Mahendra G. Patel)
Managing Director

Created with

 **nitro**PDF[®] professional

download the free trial online at nitropdf.com/professional